Angiodynamics, Inc. · NASDAQ:ANGO
Angiodynamics — Q1 2027 Earnings Presentation
11 slides from Angiodynamics's earnings presentation, Oct 8, 2026
Slide 1: First Quarter FY 2027 Earnings Results
First Quarter FY 2027 Earnings Results October 8, 2026
Slide 2: Forward looking statements
Forward looking statements Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations,
Slide 3: Leadership Transition
Leadership Transition Eric Honroth named President and Chief Executive Officer, succeeding Jim Clemmer • Eric Honroth appointed President and Chief Executive Officer and a member of the Board of Directors, effective November 2, 2026, succeeding Jim Clemmer • Follows a comprehensive Board-led search
Slide 4: Q1 FY 2027 Key Takeaways
Q1 FY 2027 Key Takeaways Continued commercial and operational execution drives AngioDynamics’ accelerated and profitable growth. YoY Revenue Total Med Tech Med Device Growth +6.9% +13.2% +1.4% Med Tech YoY Auryon Mech Thrombectomy NanoKnife Probes Revenue Growth +14.7% 6.7% +24.1% • Net sales of $80
Slide 5: Q1 FY 2027 Financial Snapshot
Q1 FY 2027 Financial Snapshot Net Sales Segment Revenue Contribution $80.9 Q1 26 Q1 27 $75.7 47% +13.2% 49% $39.9 51% $35.3 Growth 53% Med Device Med Tech Med Device Med Tech +1.4% Segment Gross Margin Growth $40.4 $41.0 52.7% 66.2% Q1 26 Q1 27 Med Device Med Tech Med Device Med Tech 5
Slide 6: Demonstrated Med Tech Growth Execution
Demonstrated Med Tech Growth Execution Pro Forma Fiscal Year Net Sales ($M) $320 $293 $271 $257 Med Tech $235 $150 $206 $127 ~47% of Total $106 Med Tech $186 $79 $96 $56 ~22% of Total $41 $157 $161 $165 $166 $170 $145 $151 FY20 A FY21 A FY22 A FY23 A FY24 A FY25 A FY26 A Med Device Med Tech 6
Slide 7: Q1 FY 2027 MedTech Performance Snapshot
Q1 FY 2027 MedTech Performance Snapshot +13.2% growth driven by solid commercial execution and continued portfolio adoption Q1 FY 2027 Sales ($M) YoY Growth Key Highlights Total Auryon $18.9 14.7% • Auryon: Double-digit growth for the 21st straight quarter, driven by our hospital atherectomy shift,
Slide 8: Fiscal Year 2027 Guidance
Fiscal Year 2027 Guidance supported by balance sheet strength Net Sales ($M) FY 2027 Financial Guidance* $336 - $341 $320 Metric Current Guidance Med Tech +12 - 15% ~50% of Net Sales $336.0M - $341.0M Med Tech Total Med Tech Net Sales +12% - 15% Growth Med Device Net Sales Flat Growth Flat Med Devic
Slide 9: Appendix
Appendix 9
Slide 10: Reconciliation of Net Loss and Diluted Loss Per Share to Non-GAAP Adjusted Net Loss
Reconciliation of Net Loss and Diluted Loss Per Reconciliation of Net Loss to Share to Non-GAAP Adjusted Net Loss and Adjusted EBITDA Diluted Loss Per Share (in thousands) (in thousands, except per share data) 10
Slide 11: Detail of Acquisition, Restructuring and Other Items, net
Detail of “Acquisition, Restructuring and Other Items, net” (in thousands) 11